These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical and microbiological evaluation of a bioabsorbable and a nonresorbable barrier membrane in the treatment of periodontal intraosseous lesions.
    Author: Smith MacDonald E, Nowzari H, Contreras A, Flynn J, Morrison J, Slots J.
    Journal: J Periodontol; 1998 Apr; 69(4):445-53. PubMed ID: 9609375.
    Abstract:
    Clinical and microbiological features of periodontal healing in barrier membrane-treated sites were determined in a randomized clinical trial. The study included 10 patients with advanced adult periodontitis and a minimum of one set of similar 2 to 3 wall intraosseous periodontal lesions with no furcation involvement. In each patient, one periodontal lesion was treated with a biodegradable membrane and a contralateral lesion with a nonresorbable barrier membrane. Within the preceding 3 months of regenerative therapy, all patients received full mouth osseous surgery except for the sites for regeneration, were instructed in oral hygiene, and were prescribed systemic ciprofloxacin and metronidazole (250 mg of each, TID, 8 days), starting 7 days before membrane placement. At baseline and at 6 months postsurgery, probing depth and clinical attachment level were assessed in each study site. The subgingival presence of suspected periodontal pathogens was determined by non-selective and selective culture and by DNA probe analyses, and of human cytomegalovirus (HCMV) and Epstein-Barr virus type 1 (EBV-1) by a nested-polymerase chain reaction detection method. At baseline, the barrier-treated sites did not differ significantly in clinical and microbial parameters. Mean baseline probing depth was 7.8+/-1.1 mm for bioabsorbable and 7.9+/-1.3 mm for nonresorbable barrier-treated sites. At 6 months, sites treated with bioabsorbable barrier revealed 4.6+/-1.7 mm gain of clinical attachment (range: 1 to 7 mm) and sites treated with nonresorbable barrier 4.2+/-2.0 mm (range: 1 to 8 mm). The 11 barrier-treated sites that harbored 10% or less bacterial pathogens and were free of HCMV and EBV-1 averaged significantly more clinical attachment gain than the 9 sites that yielded more than 10% bacterial pathogens and/or test viruses (5.6 mm versus 3.0 mm; P=0.005). The present data suggest bioabsorbable and nonresorbable barriers provide similar clinical healing of 2 to 3 wall intraosseous periodontal lesions, emphasize the importance of controlling bacterial pathogens prior to and during periodontal healing, and point to the possible detrimental role of HCMV and EBV-1 in periodontal repair.
    [Abstract] [Full Text] [Related] [New Search]